2015年1月6日讯/生物谷BIOON/--辉瑞今日宣布收购Redvax控股股权，进一步扩展了自身的疫苗业务，此番收购为辉瑞增加了临床前人类巨细胞病毒（CMV）疫苗、知识产权以及与一项未披露业务相关的技术平台。
Redvax研发过多组分病毒样颗粒以及其他蛋白组分，在疫苗研发领域占有重要的一席之地，辉瑞认为CMV疫苗是一个巨大的市场，CMV是一种疱疹病毒，可以感染50—90%的成人，而其中大部分人无症状。
Redvax的常务董事及CEO Christian Schaub表示，Redvax的资产与辉瑞的技术、资源整合之后，可以极大地推动该疫苗的研发。同时，辉瑞疫苗研发部门的Kathrin U. Jansen补充道，辉瑞与Redvax整合后将研发更多创新性的疫苗，来满足预防和治疗各种严重疾病的需求。
辉瑞的疫苗业务——Prevnar家族在2013年收获了39.74亿美元的巨额销量，位于当年所有制药公司疫苗销售之首，而此番收购更是为辉瑞疫苗业务增添了一员猛将。
辉瑞的Prevnar家族在2014年前9个月的销售额增加了11%，达到31.63亿美元。其中，最主要的销售额来源是第三季度美国政府购买了大量的Prevnar 13，其销量一度上涨了26%。
如今，辉瑞在疫苗业务上最大的一次行动是2014年6月花了6.35亿美元收购了Baxter的两款疫苗和相关的生产设施，一个是NeisVac-C，用于预防C型脑膜炎球菌感染引发的脑膜炎；另一个是FSME-IMMUN，用于预防森林脑炎（由由黄病毒属中蜱传脑炎病毒所致的中枢神经系统急性传染病，蜱为其传播媒介）。辉瑞还同意收购Baxter在澳大利亚的生产设备。
原文 Pfizer Buys Redvax， Boosting Vaccine Portfolio
Pfizer said today it acquired a controlling interest in Redvax for an undisclosed price. The deal continues the pharma giant’s expansion of its vaccine portfolio with a preclinical humancytomegalovirus (CMV) candidate， as well as intellectual property and a technology platform related to a second， undisclosed program.
Redvax develops multicomponent virus-like particles (VLPs) and other protein assemblies for vaccine development. Pfizer sees a significant market in a vaccine against CMV， a herpes virus， because it infects 50-90% of the adult population， with a majority remaining asymptomatic， according to the company.
“We believe that combining Redvax’s assets with Pfizer’s commitment， expertise and resources will significantly enhance the potential of developing this important vaccine，” said Christian Schaub， Redvax managing director and CEO of Redbiotec， from which Redvax has been spun out.
Added Kathrin U. Jansen， Ph.D.， Pfizer svp & CSO， vaccine research & early development： “We are working to bring innovative vaccines to market that prevent and treat serious diseases.”
The deal also continues Pfizer’s expansion of its vaccine portfolio， anchored by its Prevnar family， which at $3.974 billion topped GEN’s List of the Top 10 Best-Selling Vaccines of 2013. While sales dipped 3.5% from 2012， Pfizer’s Prevnar family enjoyed a comeback in 2014 with sales rising 11% in the first nine months of 2014， to $3.163 billion.
A key driver in Prevnar’s 2014 sales gain was Uncle Sam： U.S. sales of Prevnar 13 jumped 26% during Q3， “primarily driven by government purchasing patterns and increased demand，” the company stated in an October 28 press release.
Until now， Pfizer’s biggest move in vaccines came in July 2014， when it shelled out $635 million for two vaccines marketed in Europe and related production facilities from Baxter—NeisVac-C， which helps protect against meningitis caused by group C meningococcal meningitis； and FSME-IMMUN， which helps protect against tick-borne encephalitis (TBE). Pfizer also agreed to buy a portion of Baxter’s facility in Orth， Austria， where the vaccines are manufactured.